Increasing the therapeutic efficacy of recombinant ADAMTS13 infusion in TTP patients using TXA may help to prevent relapse and reduce the number of plasma exchange treatments required to achieve remission. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.